ArriVent BioPharma, Inc.
NASDAQ: AVBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Nasdaq Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhengbin Yao
- Employees
- 77
- Headquarters
- Newtown Square, United States
- IPO year
- 2024
- Market cap
- $1.5B
- Website
- https://arrivent.com
Loading AVBP…
Loading profile data…Frequently asked questions about AVBP
What does ArriVent BioPharma, Inc. (AVBP) do?
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials acros...
Where does AVBP trade?
ArriVent BioPharma, Inc. (AVBP) trades on the Nasdaq Global Market.
What sector is AVBP in?
ArriVent BioPharma, Inc. (AVBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ArriVent BioPharma, Inc.?
Zhengbin Yao is the chief executive officer of ArriVent BioPharma, Inc. (AVBP).
Where is ArriVent BioPharma, Inc. headquartered?
ArriVent BioPharma, Inc. is headquartered in United States.
Does AVBP pay a dividend?
ArriVent BioPharma, Inc. (AVBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVBP go public?
ArriVent BioPharma, Inc. (AVBP) completed its initial public offering in 2024.